New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2012
16:25 EDTOTT, AZN, WMT, ACHN, RDEA, TWC, BKS, KOn The Fly: Closing Wrap
Stocks on Wall Street were lower following a pair of political developments in Europe. France’s incumbent president, Nicolas Sarkozy, came in second in the first round of the nation's elections and the Dutch cabinet failed to gain approval for a budget which included austerity measures, leading to their resignations. The European news, along with some disappointing data there and from China, weighed on the futures, which in turn led to a sharply lower open for the broader market. The market continued to move lower in the first hour of trading but then found a level where it began to build. The averages moved in a generally upward trend for the remainder of the session, as investors waited for the next round of earnings reports and for news later this week from the FOMC... ECONOMIC EVENTS: Domestically, little economic data of note was reported. Internationally, Markit's European composite purchase managers' index fell to 47.4 points while a flash Chinese PMI reading rose to 49.1 in April, with both of those figures signaling contraction... COMPANY NEWS: The New York Times said Wal-Mart (WMT) attempted to cover up bribery that it discovered at Wal-Mart de Mexico (WMMVY) and the retailers' shares were the Dow's worst performer, falling $2.91, or 4.66%, to $59.54... Kellogg (K) cut its full-year guidance as it said Europe's challenges were "more significant" than it expected and it sees Q1 challenges in some categories in the U.S. Shares sank $3.29, or 6.09%, to $50.70... MAJOR MOVERS: Among the notable gainers were Ardea Biosciences (RDEA), up $10.78, or 51.73%, to $31.62, after AstraZeneca (AZN) agreed to acquire the company for $32 per share, and Barnes & Noble (BKS), up $2.07, or 18.25%, to $13.41, as CNBC reported that Jana Partners is increasing its stake in the company to about 12%. Noteworthy losers included Achillion (ACHN), down $1.53, or 18.54%, to $6.74, following the company's report of Phase II study data for its lead hepatitis C treatment, and Otelco (OTT), down $5.37, or 44.64%, to $6.66, after it said Time Warner Cable (TWC) will not renew its existing contract for wholesale network connections, which made up almost 12% of Otelco’s consolidated revenue last year... INDICES: The Dow fell 102.09, or 0.78%, to 12,927.17; the Nasdaq dropped 30.00, or 1.00%, to 2,970.45; and the S&P 500 shed 11.59, or 0.84%, to 1,366.94.
News For WMT;K;RDEA;AZN;BKS;ACHN;OTT;TWC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 30, 2015
07:29 EDTTWCTime Warner Cable reports Q2 residential video net declines of 45K
Subscribe for More Information
07:25 EDTAZNCharles River, AstraZeneca renew strategic partnership agreement
Charles River Laboratories International (CRL) announced that it has extended its initial three-year partnership with AstraZeneca (AZN) for an additional five-year period. Under the agreement, which extends into 2020, Charles River retains its position as AstraZeneca’s preferred strategic partner for outsourced regulated safety assessment and development DMPK.
06:06 EDTTWCTime Warner Cable reports Q2 adjusted EPS $1.54, consensus $1.81
Subscribe for More Information
05:57 EDTAZNRoche submits filing to FDA for companion diagnostic for NSCLC drug therapy
Roche announced it has submitted the cobas EGFR Mutation Test v2 for Premarket Approval, or PMA, to the FDA, as a companion diagnostic test for AZD9291, an AstraZeneca (AZN) investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation. Patients with non-small cell lung cancer who have adenocarcinoma with tumor containing an EGFR sensitizing mutation show significant benefit from currently available EGFR TKI therapies. However, approximately two-thirds of these patients will relapse and develop drug resistance. In many cases, this resistance is caused by an acquired mutation called T790M. The cobas EGFR v2 test can aid clinicians to appropriately select NSCLC patients who have acquired the T790M mutation and are most likely to benefit from AstraZeneca's novel therapy.
July 29, 2015
15:08 EDTTWCNotable companies reporting before tomorrow's open
Subscribe for More Information
July 28, 2015
18:08 EDTWMTWal-Mart warns suppliers to comply with labeling laws, WSJ reports
Last week, Wal-Mart sent a memo to hundreds of suppliers warning them to comply with labeling laws, noting that the amount inside a package should match what is printed on the outside, the Wall Street Journal reports. Reference Link
14:55 EDTWMTEarnings Watch: MasterCard reports after peers warn of currency headwinds
Subscribe for More Information
07:20 EDTAZNBrookings Institute to hold a public meeting
Subscribe for More Information
July 27, 2015
05:25 EDTAZNGenzyme acquires Caprelsa from AstraZeneca for $300M
Genzyme, a Sanofi (SNY) company, announced that it has entered into a definitive agreement with AstraZeneca (AZN) to acquire Caprelsa, a rare disease therapy, indicated for the treatment of symptomatic or progressive medullary thyroid carcinoma in patients with unresectable locally advanced or metastatic disease. Caprelsa is an oral kinase inhibitor treatment and is currently available in 28 countries. Caprelsa is in Phase III development for differentiated thyroid carcinoma, with the study expected to finish in the second half of 2015. Under the terms of the agreement, Genzyme will pay AstraZeneca up to $300M, including an upfront payment of $165M to acquire the global rights to sell and further develop Caprelsa, and further development and sales milestone payments of up to $135M. The transaction does not include the transfer of any AstraZeneca employees or facilities.
July 24, 2015
17:33 EDTBKSS&P announces changes to S&P 400, 500, and 600 indices
Subscribe for More Information
11:00 EDTKKellogg increases quarterly dividend 2%
Subscribe for More Information
06:37 EDTWMTWal-Mart increases offerings in baby category
Subscribe for More Information
July 23, 2015
19:24 EDTWMTWal-Mart's Apple Pay competitor launching soon, Bloomberg says
CurrentC, the mobile payment application funded by Wal-Mart (WMT), Target (TGT), Best Buy (BBY) and others, will see an early trial run next month, Bloomberg reported earlier, citing three people familiar with the situation. A spokesperson for Lowe's (LOW) said the consortium behind the app expects an official launch in Q3, and Bloomberg noted that CurrentC will compete with more "established" offerings such as Apple's (AAPL) Apple Pay and Google's (GOOG) Android Pay. Reference Link
17:07 EDTTWCSoroban Capital Partners reports 5% passive stake in Time Warner Cable
Subscribe for More Information
05:08 EDTWMTWal-Mart acquires remaining shares of Yihaodian
Subscribe for More Information
July 22, 2015
13:58 EDTAZNPiper cuts Array target by only 50c after failed trial
Piper Jaffray analyst Edward Tenthoff says selumetinib for Uveal Melanoma is a small indication and represented only a small part of his valuation for Array BioPharma (ARRY). As such, after partner AstraZeneca (AZN) announced that selumetinib failed in the Phase III trial, the analyst cut his price target for Array by only 50c to $14.50. The primary drivers for Array remain binimetinib and encorafenib in NRAS and BRAF melanoma and low-grade serous ovarian cancer, the analyst tells investors in a research note. He keeps an Overweight rating on the stock.
13:25 EDTWMTWal-Mart to end overnight hours at certain stores, Bloomberg reports
Subscribe for More Information
09:07 EDTAZNOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTWMTNRF cuts 2015 retail sales growth forecast to 3.5% from 4.1%
Subscribe for More Information
05:12 EDTAZNAstraZeneca says Phase 3 study of selumetinib did not meet primary endpoint
AstraZeneca (AZN) announced that the Phase 3 SUMIT study of selumetinib in combination with dacarbazine for the treatment of patients with metastatic uveal melanoma did not meet its primary endpoint of progression free survival. This combination therapy showed an adverse event profile generally consistent with current knowledge of the safety profiles of dacarbazine and selumetinib. A full evaluation of the data is ongoing. Selumetinib is a MEK inhibitor in late-stage development, with a primary Phase 3 program in second-line KRAS-mutant advanced non-small cell lung cancer in combination with docetaxel. Selumetinib is also being investigated in a Phase 3 study in differentiated thyroid cancer and in a Phase 2 registration study in patients with neurofibromatosis Type 1. Selumetinib is an oral small molecule MEK inhibitor invented by Array BioPharma (ARRY) and licensed to AstraZeneca in 2003.
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use